NCT06470347View on ClinicalTrials.gov

A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2025

Conditions
HER-2 Positive Advanced Breast Cancer
Interventions
DRUG

A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy

During treatment, subjects were given 400 mg pyrrotinib once daily, within 30 minutes after breakfast.

Trial Locations (1)

Unknown

RECRUITING

Affiliated Hospital of Zunyi Medical University, Zunyi

All Listed Sponsors
lead

Zunyi Medical College

OTHER